DARU-Journal of Pharmaceutical Sciences

Papers
(The H4-Index of DARU-Journal of Pharmaceutical Sciences is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-07-01 to 2026-07-01.)
ArticleCitations
Multi-functionalization of reduced graphene oxide nanosheets for tumor theragnosis: Synthesis, characterization, enzyme assay, in-silico study, radiolabeling and in vivo targeting evaluation67
Hybrid derivatives containing dimethyl fumarate and benzothiazole scaffolds for the potential treatment of multiple sclerosis; in silico & in vivo study36
New psychoactive substances: a multidisciplinary review of challenges and their diverse character25
Dispersive micro-solid phase extraction based on two MOFs as highly effective adsorbents for analysis of nilotinib in plasma and wastewater24
Aprepitant’s neuroprotective effects on methylphenidate-induced biochemical/mitochondrial dysfunction, neuroinflammation, and mood-related behavior alterations24
Effect of vitamins C and E on cancer survival; a systematic review23
Lipid nanoparticles for gene therapy in ocular diseases22
Co-delivery of SN38 and rapamycin albumin bound nanoparticles against breast Cancer21
Bridging solubility, stability, and translation: advances in carbon nanotube–based drug delivery systems19
Evaluation of clinical and safety outcomes of generic tacrolimus (Suprotac $$\circledR$$) versus branded tacrolimus (Prograf $$\circledR$$) in de novo liver transplant patients: a randomized clinical 19
Pharmacogenetic DPYD allele variant frequencies: A comprehensive analysis across an ancestrally diverse Iranian population19
Oral regimen for high dose methotrexate urine alkalinization: a systematic review and meta-analysis18
Stearyl amine tailored spanlastics embedded within tetronic® nanogel for boosting the repurposed anticancer potential of mebendazole: formulation, in vitro profiling, cytotoxicity assessment, and in v17
Impact of concerning excipients on animal safety: insights for veterinary pharmacotherapy and regulatory considerations14
0.096081018447876